• KSII Transactions on Internet and Information Systems (TIIS)
• /
• v.7 no.1
• /
• pp.1-21
• /
• 2013

The release of IEEE 802.15.4e specification significantly develops IEEE 802.15.4. The most inspiring improvement is the enhancement for medium access control (MAC) sublayer. To study the performance of IEEE 802.15.4e MAC, in this paper we first present an overview of IEEE 802.15.4e and introduce three MAC mechanisms in IEEE 802.15.4e. And the major concern here is the Time Slotted Channel Hopping (TSCH) mode that provides deterministic access and increases network capacity. Then a detailed analytical Markov chain model for TSCH carrier sense multiple access with collision avoidance (CSMA-CA) is presented. Expressions which cover most of the crucial issues in performance analysis such as the packet loss rate, energy consumption, normalized throughput, and average access delay are presented. Finally the performance evaluation for the TSCH mode is given and we make a comprehensive comparison with unslotted CSMA-CA in non-beacon enabled mode of IEEE 802.15.4. It can validate IEEE 802.15.4e network can provide low energy consumption, deterministic access and increase network capacity.

• The KIPS Transactions:PartB
• /
• v.13B no.6 s.109
• /
• pp.579-584
• /
• 2006

This paper proposes a nonlinear template matching measure, called counting measure, as a signal detection measure that is defined as the number of on pixels in the spot area. It is applied to classify probes for an on-off type DNA chip, where each probe spot is classified as hybridized or not. The counting measure also incorporates the maximum response search method, where the expected signal is obtained by taking the maximum among the measured responses of the various positions and sizes of the spot template. The counting measure was compared to existing signal detection measures such as the normalized correlation and the median for 2390 patient samples tested on the human papiliomavirus (HPV) DNA chip. The counting measure performed the best regardless of whether or not the maximum response search method was used. The experimental results showed that the counting measure combined with the positional search was the most preferable.

• Journal of Internet Computing and Services
• /
• v.17 no.6
• /
• pp.25-31
• /
• 2016

Recently, with greatly improving the wireless communication technology, new services are created using smart sensors, i.e., machine-to-machine (M2M) and Internet of Things (IoT). In this paper, we propose a novel IoT device (IoTD) personalization method that adopt Small-cell Access Points (SAPs) to control IoTDs using user equipments (UEs), e.g., smart phones and tablet PC, from service users. First, we introduce a system architecture that consists of UE, IoTD, and SAP and propose the IoTD personalization method with two procedures, i.e., IoTD profile registration procedure and IoTD control procedure. Finally, through simulations, we evaluated the system performance of the proposed scheme and it is shown that the proposed scheme outperforms the conventional scheme in terms of the packet delay, packet loss probability, and normalized throughput.

• Journal of Korean Neurosurgical Society
• /
• v.67 no.5
• /
• pp.510-520
• /
• 2024

Objective : Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases, characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. The treatment of PD aims to alleviate motor symptoms by replacing the reduced endogenous dopamine. Currently, there are no disease-modifying agents for the treatment of PD. Zebrafish (Danio rerio) have emerged as an effective tool for new drug discovery and screening in the age of translational research. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is known to cause a similar loss of dopaminergic neurons in the human midbrain, with corresponding Parkinsonian symptoms. L-type calcium channels (LTCCs) have been implicated in the generation of mitochondrial oxidative stress, which underlies the pathogenesis of PD. Therefore, we investigated the neuro-restorative effect of LTCC inhibition in an MPTP-induced zebrafish PD model and suggested a possible drug candidate that might modify the progression of PD. Methods : All experiments were conducted using a line of transgenic zebrafish, Tg(dat:EGFP), in which green fluorescent protein (GFP) is expressed in dopaminergic neurons. The experimental groups were exposed to 500 μmol MPTP from 1 to 3 days post fertilization (dpf). The drug candidates : levodopa 1 mmol, nifedipine 10 μmol, nimodipine 3.5 μmol, diethylstilbestrol 0.3 μmol, luteolin 100 μmol, and calcitriol 0.25 μmol were exposed from 3 to 5 dpf. Locomotor activity was assessed by automated tracking and dopaminergic neurons were visualized in vivo by confocal microscopy. Results : Levodopa, nimodipine, diethylstilbestrol, and calcitriol had significant positive effects on the restoration of motor behavior, which was damaged by MPTP. Nimodipine and calcitriol have significant positive effects on the restoration of dopaminergic neurons, which were reduced by MPTP. Through locomotor analysis and dopaminergic neuron quantification, we identified the neuro-restorative effects of nimodipine and calcitriol in zebrafish MPTP-induced PD model. Conclusion : The present study identified the neuro-restorative effects of nimodipine and calcitriol in an MPTP-induced zebrafish model of PD. They restored dopaminergic neurons which were damaged due to the effects of MPTP and normalized the locomotor activity. LTCCs have potential pathological roles in neurodevelopmental and neurodegenerative disorders. Zebrafish are highly amenable to high-throughput drug screening and might, therefore, be a useful tool to work towards the identification of disease-modifying treatment for PD. Further studies including zebrafish genetic models to elucidate the mechanism of action of the disease-modifying candidate by investigating Ca2+ influx and mitochondrial function in dopaminergic neurons, are needed to reveal the pathogenesis of PD and develop disease-modifying treatments for PD.